ULURU Inc. Extends The International Altrazeal® License To Include
Additional Territories
ADDISON, Texas, Sept. 5, 2013 /PRNewswire/ -- ULURU
Inc. (OTCQB: ULUR), today announced that it has extended the
territory for the International License for Altrazeal®,
to include Africa (markets not
already licensed), Latin America,
the Commonwealth of Independent States, Georgia, Ukraine and Turkmenistan.
Under the terms of the license extension with Altrazeal AG, our
current European distributor, ULURU will receive an up-front
licensing payment, will supply Altrazeal® at an agreed
upon price, and will receive a royalty on sales within the
territory. The licensing entity, Altrazeal AG, is the European
marketing entity which ULURU has an ownership interest of 25%.
Commenting on the extension of the territory, Helmut Kerschbaumer, Chairman of Altrazeal AG,
stated, "We have extensive business contacts in these territories.
In fact, we have already secured marketing and distribution
partners in additional key markets including South Africa. We are at advanced stages of
negotiation with other potential partners and anticipate that
Altrazeal® will be launched in a number of these markets
prior to the year end."
Altrazeal® is a scientifically engineered advanced
wound dressing designed to incorporate the desired features and
benefits of the ideal wound dressing. Altrazeal®
competes in the advanced wound dressing market which, worldwide, is
estimated to be $6.5 billion growing
annually at 13%. Altrazeal® has demonstrated potential
clinical and economic advantages in a number of chronic and acute
wounds including diabetic foot ulcers, venous ulcers and geriatric
wounds.
Commenting on the extension of the License Agreement,
Kerry P. Gray, President and CEO of
ULURU, stated, "Significant progress has been made establishing
marketing and distribution partners in this expanded territory. We
are very pleased with the progress to date in areas where,
previously, we had not anticipated commercial activities at this
time. The demonstrated features and benefits of Altrazeal,
including clinical and economic benefits, have rapidly attracted
possible partners throughout the region. I see this as exciting
progress validating the commercial potential of
Altrazeal®. We are working closely with Altrazeal AG to
as rapidly as possible launch Altrazeal® in these
markets."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on
the development of a portfolio of wound management and oral care
products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative
Nanoflex® Aggregate technology and OraDisc™ transmucosal
delivery system. For further information about ULURU Inc.,
please visit our website at www.ULURUinc.com. For further
information about Altrazeal®, please visit
www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended. These statements are subject to
numerous risks and uncertainties, including but not limited to the
launch of Altrazeal® in the territory, the commercial
potential of Altrazeal® and the demonstration of cost
savings and clinical benefits, and the risk factors detailed in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2012, and other reports
filed by us with the Securities and Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.